RESUMO
Latent infections with periodic reactivation are a common outcome after acute infection with many viruses. The latency-associated transcript (LAT) gene is required for wild-type reactivation of herpes simplex virus (HSV). However, the underlying mechanisms remain unclear. In rabbit trigeminal ganglia, extensive apoptosis occurred with LAT(-) virus but not with LAT(+) viruses. In addition, a plasmid expressing LAT blocked apoptosis in cultured cells. Thus, LAT promotes neuronal survival after HSV-1 infection by reducing apoptosis.
Assuntos
Apoptose , Herpesvirus Humano 1/fisiologia , Ceratite Herpética/patologia , Ceratite Herpética/virologia , Neurônios/patologia , Latência Viral/genética , Animais , Linhagem Celular , Genes Virais , Herpesvirus Humano 1/genética , Imuno-Histoquímica , Marcação In Situ das Extremidades Cortadas , Mutação , Neurônios/virologia , Poli(ADP-Ribose) Polimerases/imunologia , Poli(ADP-Ribose) Polimerases/metabolismo , Coelhos , Transcrição Gênica , Gânglio Trigeminal/patologia , Gânglio Trigeminal/virologia , Ativação ViralRESUMO
To create an oncolytic herpes simplex virus type 1 (HSV-1) that is inhibited for reactivation, we constructed a novel herpes recombinant virus with deletions in the gamma34.5 and LAT genes. The LAT gene was replaced by the gene for green fluorescent protein, thereby allowing viral infection to be followed. This virus, designated DM33, is effective in killing primary and established human glioma cell lines in culture. DM33 is considerably less virulent following intracerebral inoculation of HSV-susceptible BALB/c mice than the wild-type HSV-1 strain McKrae. The safety of this virus is further supported by the retention of its sensitivity to ganciclovir and its relatively limited toxicity against cultured human neuronal cells, astrocytes, and endothelial cells. The ability of DM33 to spontaneously reactivate was tested in a rabbit ocular infection model that accurately depicts human herpes infection and reactivation. Following ocular infection of rabbits, spontaneous reactivation was detected in 83% (15/18) of the eyes infected with wild-type McKrae. In contrast, none of the eyes infected with DM33 had detectable reactivation. The efficacy of this virus in cultured human glioma cell lines, its safety, confirmed by its inability to reactivate, and its attenuated neurovirulence make DM33 a promising oncolytic agent for tumor therapy.
Assuntos
Proteínas Adaptadoras de Transdução de Sinal , Neoplasias Encefálicas/terapia , Proteínas de Transporte/genética , Deleção de Genes , Genes Virais , Glioma/terapia , Herpesvirus Humano 1/genética , Proteínas de Membrana , Fosfoproteínas/genética , Proteínas Virais/genética , Ativação Viral/genética , Animais , Antivirais/farmacologia , Neoplasias Encefálicas/patologia , Proteínas de Transporte/metabolismo , Linhagem Celular , Sobrevivência Celular , Resistência a Medicamentos , Feminino , Ganciclovir/farmacologia , Terapia Genética , Glioma/patologia , Proteínas de Fluorescência Verde , Proteínas Luminescentes/metabolismo , Camundongos , Mutação , Fosfoproteínas/metabolismo , Coelhos , Proteínas Virais/metabolismo , Virulência/genética , Latência Viral/genética , Replicação Viral/genéticaRESUMO
Acyclovir (3 percent ointment) used topically one to five times a day on acute ocular herpes simplex virus (HSV) infection gave beneficial results as measured by a reduction in corneal involvement, conjunctivitis, iritis, and corneal clouding. Early intensive acyclovir topical treatment every two hours beginning 24 hours after inoculation prevented all but conjunctivitis. Topical treatments did not prevent the establishment of latent HSV infection. Effects of topical acyclovir treatment on rabbit eyes infected with parent McKrae, idoxuridine-resistant, and vidarabine-resistant strains of HSV-1 were studied. Topical acyclovir therapy given four times a day was significantly more effective than idoxuridine and vidarabine in suppressing acute herpetic ocular disease induced by either sensitive or drug-resistant strains of HSV-1. Virus isolation from neural tissues indicated that none of the therapy prevented viral infection in the nervous system. Intravenous acyclovir used twice a day (50 mg/kg) on rabbits with latent HSV infection appeared to suppress HSV in the nervous system but did not eradicate established latent HSV infection.
Assuntos
Antivirais/uso terapêutico , Guanina/análogos & derivados , Ceratite Dendrítica/tratamento farmacológico , Aciclovir , Administração Tópica , Animais , Antivirais/administração & dosagem , Córnea/microbiologia , Resistência Microbiana a Medicamentos , Guanina/administração & dosagem , Guanina/uso terapêutico , Injeções Intravenosas , Masculino , Coelhos , Simplexvirus/isolamento & purificação , Simplexvirus/fisiologia , Fatores de Tempo , Trifluridina/uso terapêutico , Gânglio Trigeminal/microbiologiaRESUMO
Vascular and parenchymal basement membranes (BMs) are thickened in diabetes, but alterations in individual BM components in diabetic eyes, especially in diabetic retinopathy (DR), are obscure. To identify abnormalities in the distribution of specific constituents, we analyzed cryostat sections of human eyes obtained at autopsy (seven normal, five diabetic without DR, and 13 diabetic with DR) by immunofluorescence with antibodies to 30 BM and extracellular matrix components. In non-DR eyes, no qualitative changes of ocular BM components were seen. In some DR corneas, epithelial BM was stained discontinuously for laminin-1, entactin/nidogen, and alpha3-alpha4 Type IV collagen, in contrast to non-DR corneas. Major BM alterations were found in DR retinas compared to normals and non-DR diabetics. The inner limiting membrane (retinal BM) of DR eyes had accumulations of fibronectin (including cellular) and Types I, III, IV (alpha1-alpha2), and V collagen. The BM zone of new retinal blood vessels in neovascularized areas accumulated tenascin and Type XII collagen, whereas normal, diabetic, and adjacent DR retinas showed only weak and irregular staining. In preretinal membranes, perlecan, bamacan, and Types VI, VIII, XII, and XIV collagen were newly identified. Diabetic BM thickening appears to involve qualitative alterations of specific BM markers at an advanced disease stage, with the appearance of DR.
Assuntos
Membrana Basal/metabolismo , Retinopatia Diabética/metabolismo , Anormalidades do Olho/metabolismo , Humanos , Neovascularização FisiológicaRESUMO
Recombinant human interferon (IFN) alpha A and alpha D combined with 1% trifluridine ophthalmic solution gave beneficial results when applied topically at a dose of 1 x 10(6) U per eye four times a day commencing 4 hr after eyes were inoculated with herpes simplex virus (HSV-1). Acute herpetic keratitis was suppressed by trifluridine alone and the combined therapies, but the high-titered interferon preparations, alone, had little effect. Duration of HSV-1 shedding into tear film during topical treatment for acute herpetic keratitis was reduced slightly by combined therapy with either IFN alpha A or IFN alpha D with trifluridine.
Assuntos
Interferon Tipo I/uso terapêutico , Ceratite Dendrítica/tratamento farmacológico , Timidina/análogos & derivados , Trifluridina/uso terapêutico , Animais , Masculino , CoelhosRESUMO
One potential complication of systemic herpes simplex virus (HSV) vaccination is that subsequent ocular infection may lead to increased immunogenic corneal scarring. Therefore, V52, a genetically engineered vaccinia virus that expresses the HSV-1 glycoprotein gD, was tested for ocular safety and for protection against ocular challenge with a stromal-disease-producing strain (McKrae) of HSV-1. To maximize immune response, rabbits were vaccinated by a series of inoculations. V52-vaccinated rabbits developed significant HSV-1 neutralizing antibody titers; however, they were not as high as those induced by vaccination with live HSV-1 McKrae. One month after the final vaccination, all rabbits were challenged ocularly. Eyes were monitored for 35 days for epithelial keratitis, stromal keratitis, and iritis. In no case was epithelial keratitis, stromal keratitis, or iritis significantly exacerbated by vaccination. The gD V52 recombinant vaccine provided protection against HSV-1 induced epithelial keratitis (P = 0.02) and long-term stromal scarring (P = 0.04). There was no significant reduction in the incidence of trigeminal ganglionic latency in the vaccinated rabbits (P greater than 0.05). Thus, our results indicate that V52, a gD recombinant vaccine probably is safe with regard to corneal scarring, and may provide a small amount of protection against ocular HSV-1 infection. The amount of protection provided was less than that reported in mice and guinea pigs. This suggests that to provide high levels of ocular protection in rabbits (and probably in humans), HSV-1 vaccines may have to elicit a more vigorous immune response than that produced by normal HSV-1 infection.
Assuntos
Ceratite Dendrítica/prevenção & controle , Vacinas Sintéticas/toxicidade , Vacinas/toxicidade , Proteínas do Envelope Viral/toxicidade , Vacinas Virais/toxicidade , Animais , Iontoforese , Irite/prevenção & controle , Ceratite Dendrítica/imunologia , Masculino , Testes de Neutralização , Coelhos , Simplexvirus/crescimento & desenvolvimento , Vaccinia virus , Ativação Viral/efeitos dos fármacosRESUMO
PURPOSE: To compare the efficacy of each of seven expressed herpes simplex virus 1 (HSV-1) glycoproteins as vaccines to protect against ocular disease after primary ocular HSV-1 infection. METHODS: Mice were vaccinated three times with equal amounts of each of seven individually expressed HSV-1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI) and then ocularly challenged with McKrae, a corneal disease-producing strain of HSV-1. Viral clearance from the eye, blepharitis, keratitis, and neovascularization were determined at various times after infection. RESULTS: Mice vaccinated with gD or gB had the best protection against eye disease. Vaccination with gI, gC, or gE produced moderate protection against eye disease. Vaccination with gG produced less protection, and vaccination with gH produced no apparent protection against eye disease. CONCLUSIONS: These results suggest that when used as vaccines, different HSV-1 glycoproteins provide different levels of protection against HSV-1-induced eye disease. Based on comparison with the authors' previously published results, the ability of each glycoprotein to protect against eye disease correlated with the ability of the glycoprotein to induce high serum neutralizing antibody titers and killer cell activity. Results suggest that the effectiveness of these seven glycoproteins in protecting against eye disease can be ranked as follows: gD > gB > gI > (gC = gE) > gG > gH.
Assuntos
Herpesvirus Humano 1/imunologia , Ceratite Herpética/prevenção & controle , Vacinação , Proteínas do Envelope Viral/imunologia , Vacinas Virais/administração & dosagem , Animais , Anticorpos Antivirais/análise , Blefarite/microbiologia , Blefarite/prevenção & controle , Córnea/imunologia , Córnea/microbiologia , Neovascularização da Córnea/prevenção & controle , Feminino , Herpesvirus Humano 1/fisiologia , Camundongos , Camundongos Endogâmicos BALB CRESUMO
Acyclovir, a new potent antiviral drug, was used to treat herpes simplex virus (HSV) infection in the rabbit ocular model. Acyclovir (3% ointment) used topically one to five times a day on acute ocular HSV infection gave beneficial results as measured by a reduction in corneal involvement, conjunctivitis, iritis, and corneal clouding. Topical treatment did not prevent the establishment of latent HSV infection. Intravenous acyclovir used two times a day (50 mg/kg) on rabbits with latent HSV infection appeared to suppress HSV in the nervous system but did not eradicate established latent HSV infection.
Assuntos
Antivirais/uso terapêutico , Guanina/análogos & derivados , Ceratite Dendrítica/tratamento farmacológico , Aciclovir , Administração Tópica , Animais , Modelos Animais de Doenças , Guanina/uso terapêutico , Injeções Intravenosas , Masculino , CoelhosRESUMO
Effects of topical acyclovir treatment on rabbit eyes infected with parent McKrae, idoxuridine-resistant, and vidarabine-resistant strains of HSV-1 were studied. Topical acyclovir therapy given four times a day was significantly more effective than idoxuridine and vidarabine at suppressing acute herpetic ocular disease induced by either sensitive or drug-resistant strains of HSV-1. Virus isolation from neural tissues indicated that none of the therapy prevented viral infection of the nervous system.
Assuntos
Antivirais/administração & dosagem , Guanina/análogos & derivados , Ceratite Dendrítica/tratamento farmacológico , Aciclovir , Animais , Resistência Microbiana a Medicamentos , Guanina/administração & dosagem , Idoxuridina/administração & dosagem , Masculino , Pomadas , Soluções Oftálmicas , Coelhos , Simplexvirus/isolamento & purificação , Vidarabina/administração & dosagem , Replicação Viral/efeitos dos fármacosRESUMO
The rabbit ocular model was used to determine if flurbiprofen, a new nonsteroidal antiinflammatory agent, caused exacerbation of herpes simplex virus (HSV) infection. Acute ocular HSV infections treated with flurbiprofen (0.1%) or dexamethasone (0.1%) drops four times a day for 10 days were similar in severity and duration as measured by corneal lesions, conjunctivitis, and corneal clouding. Eyes receiving placebo healed more rapidly than eyes treated with either anti-inflammatory drug. This preliminary study suggests that flurbiprofen appears to be comparable with dexamethasone in clinical exacerbation of acute ocular HSV infection.
Assuntos
Dexametasona/uso terapêutico , Flurbiprofeno/uso terapêutico , Ceratite Dendrítica/tratamento farmacológico , Propionatos/uso terapêutico , Animais , Dexametasona/efeitos adversos , Flurbiprofeno/efeitos adversos , CoelhosRESUMO
Iontophoresis of epinephrine into the cornea of previously infected mice was used in an attempt to induce reactivation of latent herpes simplex virus (HSV) infection of the trigeminal ganglia. BALB/c mice infected with HSV-1 strain McKrae following corneal scarification developed a latent infection of the trigeminal ganglia within 15 days. At 28 days postinfection, mice were subjected to a 3-day cycle of iontophoresis of epinephrine (0.01%) into the cornea. Ocular shedding of HSV occurred in 16/23 (70%) of stimulated mice; these animals did not shed HSV in the 3-day period prior to iontophoresis. Spontaneous shedding of HSV, however, was noted in 3/97 (3%) mice not subjected to epinephrine iontophoresis. "Infectious" virus was isolated only from the trigeminal ganglia of stimulated mice, whereas "latent" virus was isolated from the trigeminal ganglia of both stimulated and nonstimulated mice. All virus isolates were verified to be HSV by neutralization with a known HSV-1 antiserum. This ocular system thus allows for the study of the full spectrum of latent HSV infections, including latency, ganglionic reactivation, and peripheral virus shedding.
Assuntos
Epinefrina/farmacologia , Ceratite Dendrítica/induzido quimicamente , Simplexvirus/crescimento & desenvolvimento , Ativação Viral/efeitos dos fármacos , Animais , Iontoforese , Ceratite Dendrítica/fisiopatologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Nervo Trigêmeo/fisiopatologiaRESUMO
PURPOSE: To determine whether the exacerbation of herpes simplex virus type-1 (HSV-1) induced corneal scarring that the authors reported previously in HSV-1 glycoprotein K (gK) vaccinated BALB/c mice challenged with HSV-1 strain McKrae was a general phenomenon independent of virus and mouse strains. To determine the gK-induced immune response leading to exacerbation of HSV-1-induced corneal scarring. METHODS: BALB/c or C57BL/6 mice were vaccinated with gK, ocularly challenged with HSV-1 strain KOS or McKrae, and the relative amount of corneal scarring determined 28 days after challenge. The T cells, total serum, or purified immunoglobulin G (IgG) isolated from gK-vaccinated mice was transferred individually to naive mice, and the affects on corneal scarring after HSV-1 challenge were determined. RESULTS: The KOS challenge of gK-vaccinated BALB/c mice resulted in significant corneal scarring (P = 0.0003), despite the fact that KOS normally produces no corneal scarring. McKrae challenge of gK-vaccinated C57BL/6 mice resulted in significant corneal scarring (P < 0.0001), despite the fact that C57BL/6 mice are normally refractory to HSV-1-induced corneal scarring. Passive transfer of total anti-gK mouse sera or purified anti-gK mouse IgG, but not adoptive transfer of total anti-gK T-cells to naive mice, resulted in exacerbation of corneal scarring after HSV-1 challenge (P < 0.0001). Mice defective for T-cell-dependent antibody production were not susceptible to exacerbation of HSV-1-induced corneal scarring by gK vaccination (P < 0.0001). CONCLUSIONS: The ability of gK vaccination to exacerbate HSV-1-induced corneal scarring was not mouse strain or HSV-1 strain specific. The gK-induced exacerbation of corneal scarring was related to anti-gK IgG. How anti-gK IgG exacerbated HSV-1 induced corneal scarring remains to be determined.
Assuntos
Anticorpos/imunologia , Cicatriz/patologia , Córnea/patologia , Ceratite Herpética/patologia , Proteínas Virais/imunologia , Animais , Baculoviridae/metabolismo , Imunoglobulina G/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Simplexvirus/genética , Especificidade da Espécie , Linfócitos T/imunologia , Linfócitos T/transplante , Vacinação , Proteínas Virais/metabolismoRESUMO
PURPOSE: To investigate the therapeutic efficacy of periocular vaccination with herpes simplex virus (HSV) recombinant glycoprotein D from HSV-1 (gD1) or HSV-2 (gD2) in decreasing HSV-induced recurrent dendritic keratitis and HSV-induced recurrent ocular shedding in rabbits latently infected with HSV-1. METHODS: Rabbits latently infected with HSV-1 were vaccinated periocularly (by subconjunctival injection) with gD1 and adjuvant, gD2 and adjuvant, or adjuvant alone. Eyes were examined daily for 49 days for recurrent herpetic keratitis and for recurrent infectious HSV-1 shedding. RESULTS: In both vaccinated groups, a significantly decreased number of eyes exhibited recurrences of herpetic keratitis compared with recurrences in adjuvant-treated control eyes (gD1 group, 27/1372, [2%]; gD2 group, 24/1274, [2%]; and control, 54/1274 [4%]; P < 0.005). Eyes in the gD1-vaccinated group (44/1308 [3.4%]; P = 0.01), but not those in the gD2-vaccinated group (71/1274 [5.6%]; P = 0.93), had significantly decreased viral shedding (positive cultures compared with total cultures) compared with eyes in the adjuvant-treated control group (69 of 1275 [5.4%]). CONCLUSIONS: Recurrent HSV-1 corneal disease was significantly reduced by therapeutic local periocular vaccination. The vaccine may be more efficacious against HSV-1-induced recurrent corneal disease than against recurrent HSV-1 ocular shedding. Its efficacy against corneal disease appeared to be longer lasting than its efficacy against recurrent spontaneous shedding. The heterotypic gD2 vaccine was as efficacious as the homotypic gD1 vaccine against recurrent corneal disease, whereas the homotypic vaccine was much more efficacious than the heterotypic vaccine against recurrent HSV-1 shedding. This is the first report in any animal model of a successful therapeutic vaccine against recurrent HSV-1-induced corneal disease. These results support the concept that development of a therapeutic vaccine for ocular HSV-1 recurrence in humans may be possible.
Assuntos
Córnea/virologia , Herpesvirus Humano 1/imunologia , Ceratite Dendrítica/prevenção & controle , Vacinação , Vacinas Virais/administração & dosagem , Acetilmuramil-Alanil-Isoglutamina/análogos & derivados , Acetilmuramil-Alanil-Isoglutamina/imunologia , Adjuvantes Imunológicos , Animais , Efeito Citopatogênico Viral , Feminino , Herpesvirus Humano 1/isolamento & purificação , Herpesvirus Humano 2/imunologia , Herpesvirus Humano 2/isolamento & purificação , Ceratite Dendrítica/imunologia , Ceratite Dendrítica/virologia , Fosfatidiletanolaminas/imunologia , Coelhos , Recidiva , Pele/virologia , Lágrimas/virologia , Vacinas de DNA/administração & dosagem , Proteínas do Envelope Viral/imunologia , Eliminação de Partículas ViraisRESUMO
2-Fluoro-5-iodo-ara-C (FIAC), a new and potent drug, was tested for antiviral activity against several strains of herpes simplex virus (HSV), types 1 and 2. Effective dose-50% (ED-50) determinations for FIAC ranged from 0.023 to 0.51 muM for HSV-2. FIAC-treated cells did not exhibit any toxicity until the drug concentration was increased 2000-fold above the ED-50 level. Ocular herpetic keratitis in New Zealand white rabbits was treated with 1.0%, 0.1%, 0.01% FIAC beginning 3 days after inoculation wit HSV-1 (McKrae strain). Topical chemotherapy was administered five times per day for 7 consecutive days. After 4 days of treatment, corneal epithelial involvement, conjunctivitis, iritis, and clouding were not detectable in eyes receiving 1.0% FIAC. Toxic reactions were not observed in rabbit eyes treated with FIAC drug. HSV was not prevented from spreading into the central nervous system when topical FIAC therapy was initiated on day 3 after inoculation.
Assuntos
Antivirais/uso terapêutico , Citarabina/análogos & derivados , Ceratite Dendrítica/tratamento farmacológico , Animais , Linhagem Celular , Células/efeitos dos fármacos , Citarabina/farmacologia , Citarabina/uso terapêutico , Técnicas In Vitro , Coelhos , Simplexvirus/efeitos dos fármacosRESUMO
PURPOSE: To address the possibility of neuronal-like herpes simplex virus type 1 (HSV-1) latency in the cornea by determining if regulation of the HSV-1 LAT promoter in stromal keratocytes is similar to LAT promoter regulation in neurons. METHODS: Transient chloramphenicol acetyltransferase (CAT) assays were used to measure the relative promoter activity of various HSV-1 LAT promoter fragments in primary human corneal cells versus neuronal and nonneuronal cells. RESULTS: The authors found that the LAT promoter, whose location they previously mapped in neurons using transient CAT assays, functioned in stromal keratocytes using the same assay system and that two regions between -283 and -1932 nucleotides relative (upstream) to the start of LAT transcription slightly increased the LAT promoter activity in stromal keratocytes. They previously showed a similar increase in neuronal cells, and a large decrease in nonneuronal cells. In addition, they found that a neuronal specific enhancer region they previously defined between -162 and -283 nucleotides upstream of the start of LAT transcription also enhanced promoter activity in stromal keratocytes. Using gel-shift assays, they detected a nuclear factor specific to neurons and stromal keratocytes that binds to the LAT promoter and that may be a LAT regulatory factor. CONCLUSIONS: Recently, it has been suggested that the cornea might serve as an alternative site of latent herpes simplex virus type 1 (HSV-1) infection. However, this remains controversial. The authors' findings suggest that corneal and neuronal cells regulate the LAT promoter similarly and that this regulation differs from that seen in nonneuronal cells. Thus, the possibility of neuronal-like latency in the cornea remains plausible.
Assuntos
Substância Própria/metabolismo , Herpesvirus Humano 1/fisiologia , Neurônios/metabolismo , Regiões Promotoras Genéticas , Animais , Células Cultivadas , Cloranfenicol O-Acetiltransferase/genética , Cloranfenicol O-Acetiltransferase/metabolismo , Substância Própria/microbiologia , Fibroblastos/metabolismo , Fibroblastos/microbiologia , Herpesvirus Humano 1/genética , Humanos , Camundongos , Neurônios/microbiologia , Ratos , Células Tumorais Cultivadas , Latência Viral/fisiologiaRESUMO
PURPOSE: To uncover abnormalities of extracellular matrix (ECM) distribution in human corneas with pseudophakic and aphakic bullous keratopathy (PBK/ABK). METHODS: Indirect immunofluorescence with antibodies to 27 ECM components was used on frozen sections of 14 normal and 20 PBK/ABK corneas. RESULTS: Fibrillar deposits of an antiadhesive glycoprotein tenascin in the anterior and posterior stroma, epithelial basement membrane (BM), bullae and subepithelial fibrosis (SEF) areas, and posterior collagenous layer (PCL) were revealed in disease corneas. Tenascin in midstroma, which was observed in some cases, correlated with decreased visual acuity. In normal central corneas, tenascin was never found. Other major ECM abnormalities in PBK/ABK corneas compared to normals included: discontinuous epithelial BM straining for laminin-1 (alpha 1 beta 1 gamma 1), entactin/nidogen and fibronectin; accumulation of fibronectin and alpha 1-alpha 2 type IV collagen on the endothelial face of the Descemet's membrane; and abnormal deposition of stromal ECM (tenascin, fibronectin, decorin, types I, III, V, VI, VIII, XII, XIV collagen) and BM components (type IV, collagen, perlecan, bamacan, laminin-1, entactin-nidogen, fibronectin) in SEF areas and in PCL. CONCLUSIONS: The study provides a molecular description of an ongoing fibrosis on the epithelial, stomal, and endothelial levels in PBK/ABK corneas. These fibrotic changes may follow initial endothelial damage after cataract surgery, may be caused by the upregulation of fibrogenic cytokines, and may play a significant role in the progression of bullous keratopathy.
Assuntos
Córnea/patologia , Doenças da Córnea/patologia , Matriz Extracelular/patologia , Idoso , Idoso de 80 Anos ou mais , Membrana Basal/metabolismo , Membrana Basal/patologia , Extração de Catarata/efeitos adversos , Córnea/metabolismo , Doenças da Córnea/etiologia , Doenças da Córnea/metabolismo , Transplante de Córnea , Matriz Extracelular/metabolismo , Proteínas da Matriz Extracelular/metabolismo , Feminino , Fibrose , Imunofluorescência , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
We previously reported that vaccination of BALB/c mice with the baculovirus expressed HSV-1 glycoprotein K (gK) or passive transfer of gK purified IgG to naive BALB/c mice causes severe exacerbation of HSV-1 induced corneal scarring following ocular challenge. In addition, a productive chronic infection, rather than a latent infection, is found in most trigeminal ganglia. These phenomena are accompanied by a very high T(H)1+T(H)2 response in the eye (Ghiasi, H., Cai, S., Nesburn, A.B., Wechsler, S.L., 1996. Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection. Virology 224, 330-333; Ghiasi, H., Cai, S., Slanina, S., Nesburn, A. B., Wechsler, S.L., 1997. Nonneutralizing antibody against the glycoprotein K of herpes simplex virus type-1 exacerbates herpes simplex virus type-1-induced corneal scarring in various virus-mouse strain combinations. Invest. Ophthalmol. Vis. Sci. 38, 1213-1221; Ghiasi, H., Hofman, F.M., Cai, S., Perng, G.C., Nesburn, A.B., Wechsler, S.L., 1999. Vaccination with different HSV-1 glycoproteins induces different patterns of ocular cytokine responses following HSV-1 challenge of vaccinated mice. Vaccine 17, 2576-2582). In the studies reported here, we investigated the hypothesis that anti-gK serum produces antibody-dependent enhancement (ADE) of ocular HSV-1 infection. We found that gK vaccinated mice had significantly higher HSV-1 titers in their eyes than gD or mock-vaccinated mice and that anti-gK sera enhanced HSV-1 infection in the macrophage cell line U937. In addition, passive transfer of anti-gK sera to naive mice 24 h prior to ocular HSV-1 challenge also increased viral replication. These results were consistent with ADE of HSV-1 by sera to gK. This suggests that the severely exacerbated corneal disease seen following HSV-1 ocular challenge of gK vaccinated mice is a result of ADE. The ability of gK sera to cause harmful ADE may impact HSV-1 vaccine development.
Assuntos
Anticorpos Antivirais/imunologia , Herpesvirus Humano 1/imunologia , Ceratite Herpética/imunologia , Proteínas Virais/imunologia , Animais , Modelos Animais de Doenças , Olho/virologia , Feminino , Herpesvirus Humano 1/fisiologia , Humanos , Imunização Passiva , Ceratite Herpética/fisiopatologia , Ceratite Herpética/virologia , Camundongos , Camundongos Endogâmicos BALB C , Replicação ViralRESUMO
A recombinant baculovirus (vAc-gB1) was constructed which expresses the glycoprotein B (gB) gene of herpes simplex virus type 1 (HSV-1). When Sf9 cells were infected with these recombinant viruses, a protein that was close in size to authentic HSV-1 gB was detected by gB polyclonal antibody. The recombinant gB was found on the membrane of Sf9 cells and was susceptible to tunicamycin, glycosidase F (PNGase F) and partially susceptible to Endo-H. Antibodies raised in mice to this recombinant recognized viral gB and neutralized the infectivity of HSV-1 in vitro. Mice inoculated with the recombinant gB were protected from lethal challenge with HSV-1.
Assuntos
Simplexvirus/imunologia , Proteínas do Envelope Viral/biossíntese , Animais , Anticorpos Antivirais/imunologia , Baculoviridae/genética , Sequência de Bases , Southern Blotting , Clonagem Molecular , DNA Viral , Ensaio de Imunoadsorção Enzimática , Imunofluorescência , Glicosilação , Herpes Simples/prevenção & controle , Cinética , Camundongos , Camundongos Endogâmicos BALB C , Dados de Sequência Molecular , Mariposas , Testes de Neutralização , Tunicamicina/farmacologia , Vacinação , Células Vero , Proteínas do Envelope Viral/genética , Proteínas do Envelope Viral/imunologiaRESUMO
Based on sequence analysis, the protein encoded by the UL3 open reading frame (ORF) of herpes simplex virus type 1 (HSV-1) was predicted to contain an N glycosylation site and to be a glycoprotein. To determine if this prediction was correct, we cloned and expressed the DNA encoding the complete sequence of the UL3 ORF in a baculovirus expression system. Western blotting was done using polyclonal antibody raised against synthetic UL3 peptides. Two major baculovirus-UL3 expressed protein bands with apparent molecular weights of 30 kDa and 31 kDa, and two minor protein bands with apparent molecular weights of 29 kDa and 33 kDa were detected. None of the expressed UL3 protein species were susceptible to tunicamycin treatment, suggesting that they were not N-linked glycosylated. Cell fractionation studies indicated that the UL3 protein was localized in the cytoplasmic and nuclear portion of the cells, rather than the cell membrane, again suggesting a lack of glycosylation. In contrast, the baculovirus expressed UL3 protein was phosphorylated as judged by 32Pi-labeling. Immunoprecipitation followed by SDS-PAGE demonstrated a single 32Pi-labeled UL3 related band with an apparent molecular weight of 33 kDa, indicating that the UL3 protein was a phosphoprotein. Antibodies produced in mice vaccinated with baculovirus-UL3 protein reacted with two UL3 related HSV-1 bands on Western blots. These protein bands had apparent molecular weights of 27 and 33 kDa and presumably represent the unphosphorylated and phosphorylated forms of UL3.
Assuntos
Herpesvirus Humano 1/genética , Proteínas Imediatamente Precoces/genética , Animais , Linhagem Celular , Expressão Gênica , Humanos , Proteínas Imediatamente Precoces/imunologia , Camundongos , Fases de Leitura Aberta , Fosfoproteínas/química , Fosfoproteínas/genética , Fosfoproteínas/imunologia , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/imunologia , Spodoptera/citologiaRESUMO
Perforin (cytolysin; pore-forming protein) is expressed in both CD8(+) cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, and is a major factor responsible for the cytolytic activities of these cells. Both CD8(+) T-cells and NK cells are important in eliminating cells infected with certain viruses. We examined the role of perforin in a mouse model of HSV-1 infection using perforin-deficient mice. Naïve perforin knockout (perforin(0/0)) mice were more susceptible to lethal HSV-1 ocular challenge (60% survival), than naïve parental C57BL/6 (100% survival). In contrast, both C57BL/6 and perforin(0/0) mice had similar levels of HSV-1 induced corneal scarring. Vaccination of perforin(0/0) mice induced a significantly higher HSV-1 neutralizing antibody titer than vaccination of C57BL/6 mice, and the mice were completely protected against lethal ocular challenge. These results suggest that in naïve mice ocularly challenged with HSV-1, the perforin pathway was involved in protection against death, but not in protection against corneal scarring.